RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis
USA - NASDAQ:RIGL - US7665597024 - Common Stock
46.22 USD
+3.71 (+8.73%)
45.11 USD
-1.11 (-2.4%)
Taking everything into account, RIGL scores 7 out of 10 in our fundamental rating. RIGL was compared to 533 industry peers in the Biotechnology industry. While RIGL has a great health rating, its profitability is only average at the moment. An interesting combination arises when we look at growth and value: RIGL is growing strongly while it also seems undervalued. These ratings would make RIGL suitable for value and growth investing!
1. Profitability
1.1 Basic Checks
RIGL had positive earnings in the past year.
In the past year RIGL had a positive cash flow from operations.
RIGL had negative earnings in 4 of the past 5 years.
In multiple years RIGL reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 46.72%, RIGL belongs to the best of the industry, outperforming 99.44% of the companies in the same industry.
RIGL's Return On Equity of 96.34% is amongst the best of the industry. RIGL outperforms 99.25% of its industry peers.
RIGL has a better Return On Invested Capital (63.44%) than 99.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 40.17%, RIGL belongs to the top of the industry, outperforming 97.19% of the companies in the same industry.
Looking at the Operating Margin, with a value of 42.17%, RIGL belongs to the top of the industry, outperforming 98.87% of the companies in the same industry.
RIGL has a better Gross Margin (93.10%) than 93.06% of its industry peers.
In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, RIGL has more shares outstanding
Compared to 5 years ago, RIGL has less shares outstanding
Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
RIGL has an Altman-Z score of -0.09. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of -0.09, RIGL is doing good in the industry, outperforming 61.54% of the companies in the same industry.
The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
RIGL's Debt to FCF ratio of 0.88 is amongst the best of the industry. RIGL outperforms 94.00% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that RIGL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.25, RIGL is doing worse than 68.29% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for RIGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.09 |
ROIC/WACC7.14
WACC8.89%
2.3 Liquidity
A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
The Current ratio of RIGL (2.28) is worse than 72.05% of its industry peers.
A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.14, RIGL is doing worse than 71.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 4307.14% over the past year.
Looking at the last year, RIGL shows a very strong growth in Revenue. The Revenue has grown by 79.13%.
The Revenue has been growing by 24.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
The Earnings Per Share is expected to grow by 29.86% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 14.40% on average over the next years. This is quite good.
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
RIGL is valuated cheaply with a Price/Earnings ratio of 7.49.
97.94% of the companies in the same industry are more expensive than RIGL, based on the Price/Earnings ratio.
RIGL is valuated cheaply when we compare the Price/Earnings ratio to 25.51, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 12.00, the valuation of RIGL can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 97.19% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of RIGL to the average of the S&P500 Index (34.98), we can say RIGL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.49 | ||
| Fwd PE | 12 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaper than 98.50% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, RIGL is valued cheaply inside the industry as 97.94% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.17 | ||
| EV/EBITDA | 5.46 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RIGL may justify a higher PE ratio.
RIGL's earnings are expected to grow with 61.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.44%
EPS Next 3Y61.96%
5. Dividend
5.1 Amount
RIGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
46.22
+3.71 (+8.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.02%
Inst Owner Change15.25%
Ins Owners2.58%
Ins Owner Change1.84%
Market Cap829.19M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts76.67
Price Target39.1 (-15.4%)
Short Float %19.68%
Short Ratio5.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)13.61%
EPS NQ rev (1m)26.13%
EPS NQ rev (3m)136.63%
EPS NY rev (1m)0%
EPS NY rev (3m)380.48%
Revenue NQ rev (1m)1.72%
Revenue NQ rev (3m)7.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)39.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.49 | ||
| Fwd PE | 12 | ||
| P/S | 2.94 | ||
| P/FCF | 12.17 | ||
| P/OCF | 12.16 | ||
| P/B | 7.05 | ||
| P/tB | 8.99 | ||
| EV/EBITDA | 5.46 |
EPS(TTM)6.17
EY13.35%
EPS(NY)3.85
Fwd EY8.33%
FCF(TTM)3.8
FCFY8.22%
OCF(TTM)3.8
OCFY8.22%
SpS15.72
BVpS6.56
TBVpS5.14
PEG (NY)0.01
PEG (5Y)N/A
Graham Number30.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.09 |
F-Score7
WACC8.89%
ROIC/WACC7.14
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y503.1%
EPS Next 2Y102.44%
EPS Next 3Y61.96%
EPS Next 5Y29.86%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year62.09%
Revenue Next 2Y26.39%
Revenue Next 3Y18.97%
Revenue Next 5Y14.4%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year470.56%
EBIT Next 3Y88.04%
EBIT Next 5YN/A
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
Can you provide the valuation status for RIGEL PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
Can you provide the expected EPS growth for RIGL stock?
The Earnings per Share (EPS) of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 503.1% in the next year.